Table 1

Patients and tumor characteristics
Characteristic Value-n(%)
Age (y)
Mean 53
Range 28-78
Gender (n)
Female 1 (3.2)
Male 30 (96.8)
Tumor site
NPC 11 (35.5)
Oral cavity 14 (45.2)
Oropharynx 4 (12.9)
Larynx 1 (3.2)
Parotid 1 (3.2)
Stage (TNM staging system)
T1 3 (9.7)
T2 12 (38.7)
T3 6 (19.4)
T4 7 (22.6)
Not applicable/Recurrent 3 (9.6)
N0 16 (51.7)
N1 5 (16.1)
N2 7 (22.6)
N3 0 (0.0)
Not applicable/Recurrent 3 (9.6)
Dose, Gy/# fractions
14 (45.2) 69.2/38
1 (3.2) 54.8/30
9 (29.1) 59.4/33
4 (12.9) 57.6/32
1 (3.2) 68.4/38
1 (3.2) 70.8/35
1 (3.2) 52.2/29
Parotid gland mean dose
Ipsilateral, mean (range) 51.7 (26.9-74.8) Gy
Contralateral, mean (range) 36.7 (7.6-57.6) Gy
Surgery before RT
Yes 16 (51.6)
No 15 (48.4)
Chemotherapy
Yes 19 (61.3)
No 12 (38.7)
SEF recovery*
Grade 3+ xerostomia 10 (16.1)
No grade 3+ xerostomia 52 (83.9)
QoL measurement*
Grade 3+ xerostomia 6 (19.4)
No grade 3+ xerostomia 25 (80.6)

*SEF recovery and QoL measurement was at 1-year after RT. Grade 3+: ≧grade 3.

Abbreviation: RT radiotherapy, SEF salivary excretion factorm, QoL quality of life.

Lee et al.

Lee et al. BMC Cancer 2012 12:567   doi:10.1186/1471-2407-12-567

Open Data